Exelixis
EXEL
#1806
Rank
HK$92.50 B
Marketcap
HK$345.02
Share price
-0.70%
Change (1 day)
26.49%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024: HK$5.32 Billion

According to Exelixis's latest financial reports the company's current earnings are HK$2.28 Billion. In 2024 the company made an earning of HK$5.32 Billion, an increase over its 2023 earnings that were of HK$2.01 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024HK$5.32 B164.69%
2023HK$2.01 B9.89%
2022HK$1.83 B-20.33%
2021HK$2.29 B124.82%
2020HK$1.02 B-67.14%
2019HK$3.11 B-11.94%
2018HK$3.53 B185.09%
2017HK$1.23 B-325.82%
2016-HK$0.55 Billion-58.12%
2015-HK$1.31 Billion-37.61%
2014-HK$2.1 Billion9.75%
2013-HK$1.92 Billion65.96%
2012-HK$1.16 Billion-291.63%
2011HK$0.60 B-195.59%
2010-HK$0.63 Billion-42.17%
2009-HK$1.09 Billion-18.98%
2008-HK$1.35 Billion-6.99%
2007-HK$1.45 Billion46.3%
2006-HK$0.99 Billion33.25%
2005-HK$0.75 Billion-30.92%
2004-HK$1.08 Billion44.29%
2003-HK$0.75 Billion12.86%
2002-HK$0.66 Billion22.79%
2001-HK$0.54 Billion60.14%
2000-HK$0.34 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
HK$253.11 B 3,609.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$92.60 B 1,257.17%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
HK$64.41 B 844.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
HK$71.10 B 942.07%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
HK$180.40 B 2,544.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
HK$62.76 B 819.85%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
HK$72.84 B 967.56%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-HK$0.26 Billion-103.73%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-HK$0.23 Billion-103.33%๐Ÿ‡บ๐Ÿ‡ธ USA